ESH MM 2018 | Investigating vaccines for hem-onc: key questions
David Avigan
• 5 Oct 2018
At a relatively early stage of development, vaccines for hematological malignancies are both exciting and challenging. In this interview, David Avigan, MD, of Harvard Medical School, Boston, MA, discusses the key questions for investigation in this field. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
